Novo Nordisk invented the GLP-1 category, told the world that weight loss was the least important thing its drugs did, and then watched a competitor take market share by promising a bigger number.
Mike Doustdar became president and CEO of Novo Nordisk in August 2025, after 34 years at the company that began with a summer job making photocopies in its Vienna office. He tells Brian Sozzi what went wrong in unusually direct terms: Wegovy’s slogan was “Beyond Weight”, the science behind it still holds, and the market simply did not want to hear it. Eli Lilly arrived second with a larger weight-loss figure and won on that alone.
His response was to stop arguing and match the number, so that the heart, kidney and liver benefits could arrive as a bonus rather than as the pitch. He also explains why he never believed the story that Ozempic was making airlines lighter, why food executives have not felt the impact yet, and what he thinks of the untested peptides people are buying online.
00:00 “It’s five people”
00:20 A year and three days in the job
01:02 The summer job making photocopies at 21
02:48 The culture that kept him for 34 years
04:43 How you get from office clerk to chief executive
07:20 Promoted after 34 years without ever working at headquarters
09:18 Day one, and the first 90 days
11:41 Admitting Novo Nordisk lost market share
13:57 How the company plans to win it back
15:56 Why Eli Lilly took share: “Beyond Weight” and 21% against 15%
19:37 Is the pill’s uptake fast enough for the market
20:56 What GLP-1s are doing in our lives in five years
23:53 The next breakthrough after the pill
25:05 Why food executives have not felt the impact yet
26:35 The airline theory he never believed
27:14 The untested peptides people buy online
30:38 The patent cliff, and the pipeline behind it
34:31 Close
Power Players with Brian Sozzi brings you candid conversations with the executives, founders and operators shaping the economy.
Subscribe to Yahoo Finance: https://yahoo.com/finance
source
